Home | Welcome to Contract Pharma   
Last Updated Thursday, May 23 2013
Print

AMRI



Published August 4, 2010
Related Searches: Financial Reports
AMRI 2Q10


2Q Revenues: $49.5 million (-4%)

2Q Loss: $3.9 million (earnings of $179,000 in 2Q09)

YTD Revenues: $98.8 million (-6%)

YTD Loss: $3.9 million (earnings of $2.1 million in 1H09)

Comments: Contract revenues for 2Q10 were $40.7 million (+5%). Discovery Services revenues were flat at $11.5 million, Development/Small Scale Manufacturing revenues were up 1% to $8.2 million, and Large Scale Manufacturing was up 10% to $21 million. For 1H10, contract revenues fell 3% to $79.6 million. The net loss was attributable to restructuring costs for U.S. operations, and the acquisition of Hyaluron. The company cited a continued shift in customer demand toward services in Europe and Asia.



blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On